Investigators believe triglyceride testing could improve viral sepsis risk more broadly based on study findings.
|Articles|March 11, 2008
NCPA issues statement on bill that would add human growth hormone to Schedule III
NCPA comments on bill that would classify human growth hormone as Schedule III substance.
Advertisement
The National Community Pharmacists Association has issued a comment on Senate Bill S877/House Bill 4911. The
Advertisement
Related to this article
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, explains how education eases inpatient switches, and how the protocol cuts costs and simplifies workflow.
Findings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.
Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.
Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.
Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Advertisement
Advertisement
Trending on Drug Topics
1
High Triglycerides Independently Linked with Severe COVID-19 Death
2
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
3
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
4
ACCESS to Pharmacy Care Model Lets Pharmacists Bill for Chronic Care
5